Adar1 Capital Management portfolio · Q3 2026
ADAR1 Capital Management, LLC · CIK 0001940272 ·13F filings on SEC EDGAR
In Q3 2026, ADAR1 Capital Management, LLC reported 272 positions worth $2.3B. Its largest holding was ABVX at 8.6% of the portfolio, and the top 10 made up 39%. Its largest new position was FRNM ($25.9M), and it sold out of CRNX.
- NEW 45
- ADD 85
- REDUCE 60
- EXIT 50
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 232 positions are grouped as one box.
Portfolio history
Q4 2025 to Q3 2026, 4 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
ABVX ABIVAX SA-ADR | 8.65% | $47.81 | $99.02 | +107.1% | $203.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPY SS SPDR S&P 500 ETF TRUST-US | 5.77% | $708.58 | $762.63 | +7.6% | $135.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 5.71% | $36.15* | $140.89 | +289.8% | $134M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 4.79% | $12.90* | $36.57 | +183.6% | $112.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZLAB ZAI LAB LTD-ADR | 3.79% | $20.50* | $26.34 | +28.5% | $89.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 3.04% | $19.64* | $33.78 | +72.0% | $71.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 1.84% | $37.15 | $37.19 | +0.1% | $43.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNLI DENALI THERAPEUTICS INC | 1.82% | $19.92 | $20.67 | +3.8% | $42.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BOXX ALPHA ARCHITECT 1-3 MNTH BOX | 1.70% | $106.78 | $118.39 | +10.9% | $39.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 1.62% | $10.96 | $39.13 | +257.2% | $38.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGIO AGIOS PHARMACEUTICALS INC | 1.61% | $36.10 | $33.25 | -7.9% | $37.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AURA AURA BIOSCIENCES INC | 1.44% | $6.30 | $6.28 | -0.3% | $33.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VKTX VIKING THERAPEUTICS INC | 1.44% | $34.58* | $32.60 | -5.7% | $33.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CYTK CYTOKINETICS INC | 1.29% | $54.37* | $65.91 | +21.2% | $30.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSM INSMED INC | 1.12% | $115.43 | $114.14 | -1.1% | $26.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 1.10% | $15.75 | $15.75 | 0.0% | $25.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLDX CELLDEX THERAPEUTICS INC | 1.10% | $30.35 | $32.41 | +6.8% | $25.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 1.07% | $5.43 | $7.77 | +43.1% | $25.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBIO BRIDGEBIO PHARMA INC | 1.06% | $58.75* | $65.80 | +12.0% | $25M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 1.05% | $328.69 | $291.23 | -11.4% | $24.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FULC FULCRUM THERAPEUTICS INC | 1.05% | $3.83* | $3.70 | -3.3% | $24.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VIR VIR BIOTECHNOLOGY INC | 1.03% | $8.96 | $11.18 | +24.8% | $24.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 1.01% | $14.16 | $11.76 | -16.9% | $23.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENTA ENANTA PHARMACEUTICALS INC | 0.97% | $14.28 | $13.18 | -7.7% | $22.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EDIT EDITAS MEDICINE INC | 0.97% | $3.24 | $2.57 | -20.7% | $22.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 0.90% | $46.92 | $89.03 | +89.7% | $21.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.86% | $39.93 | $45.84 | +14.8% | $20.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 0.82% | $23.41 | $23.71 | +1.3% | $19.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SNY SANOFI-ADR | 0.82% | $42.06 | $41.23 | -2.0% | $19.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 0.76% | $45.37 | $205.26 | +352.4% | $18M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRPT SAREPTA THERAPEUTICS INC | 0.74% | $19.65* | $18.22 | -7.3% | $17.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MAZE MAZE THERAPEUTICS INC | 0.74% | $29.33 | $27.18 | -7.3% | $17.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANL ADLAI NORTYE GROUP LTD | 0.68% | $10.97 | $16.00 | +45.9% | $16M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLYB RALLYBIO CORP | 0.68% | $15.84 | $17.20 | +8.6% | $15.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NKTR NEKTAR THERAPEUTICS | 0.67% | $64.54 | $60.54 | -6.2% | $15.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
URGN UROGEN PHARMA LTD | 0.64% | $26.03 | $40.63 | +56.1% | $15M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 0.63% | $2.53* | $4.87 | +92.6% | $14.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNPR MONOPAR THERAPEUTICS INC | 0.61% | $49.36 | $79.67 | +61.4% | $14.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JANX JANUX THERAPEUTICS INC | 0.61% | $19.27 | $17.28 | -10.3% | $14.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 0.56% | $81.23 | $95.22 | +17.2% | $13.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRTA PROTHENA CORP PLC | 0.54% | $6.36 | $8.38 | +31.9% | $12.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COGT COGENT BIOSCIENCES INC | 0.53% | $32.23 | $32.02 | -0.6% | $12.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REGN REGENERON PHARMACEUTICALS | 0.53% | $605.67 | $758.27 | +25.2% | $12.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIL SS SPDR BB 1-3M T-BILL ETF | 0.53% | $91.43* | $91.64 | +0.2% | $12.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TENX TENAX THERAPEUTICS INC | 0.52% | $0.44 | $1.89 | +329.3% | $12.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GLUE MONTE ROSA THERAPEUTICS INC | 0.51% | $10.97 | $11.93 | +8.7% | $12M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABCL ABCELLERA BIOLOGICS INC | 0.51% | $14.59 | $14.59 | 0.0% | $12M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ESTA ESTABLISHMENT LABS HOLDINGS | 0.51% | $56.29 | $64.17 | +14.0% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VOGX VOGENX INC | 0.51% | $22.79 | $22.79 | 0.0% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IKT INHIBIKASE THERAPEUTICS INC | 0.50% | $2.72 | $2.06 | -24.5% | $11.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OVID OVID THERAPEUTICS INC | 0.48% | $2.06* | $2.49 | +20.8% | $11.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVLN AVALYN PHARMA INC | 0.48% | $30.12 | $28.49 | -5.4% | $11.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TEVA TEVA PHARMACEUTICAL IND LTD | 0.47% | $39.60 | $39.60 | 0.0% | $10.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 0.46% | $19.68 | $24.95 | +26.8% | $10.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 0.45% | $4.89 | $29.10 | +495.4% | $10.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HLXC HELIX ACQUISITION CORP-CL A | 0.45% | $10.23 | $10.57 | +3.3% | $10.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZNTL ZENTALIS PHARMACEUTICALS INC | 0.44% | $3.01 | $2.77 | -8.0% | $10.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BEAM BEAM THERAPEUTICS INC | 0.44% | $24.45 | $24.45 | 0.0% | $10.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VOR VOR BIOPHARMA INC | 0.43% | $18.41 | $19.08 | +3.6% | $10.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.42% | — | — | — | $10M | |
EWTX EDGEWISE THERAPEUTICS INC | 0.42% | $33.54 | $40.60 | +21.1% | $9.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KZIA KAZIA THERAPEUTICS-SPON ADR | 0.40% | $9.88 | $9.59 | -2.9% | $9.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLYM CLIMB BIO INC | 0.39% | $7.36 | $11.47 | +55.8% | $9.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.37% | — | — | — | $8.7M | |
REPL REPLIMUNE GROUP INC | 0.37% | $5.89 | $13.24 | +124.9% | $8.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRD OPUS GENETICS INC | 0.37% | $4.50 | $4.84 | +7.7% | $8.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SMMT SUMMIT THERAPEUTICS INC | 0.36% | $17.15 | $16.91 | -1.4% | $8.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCVX VAXCYTE INC | 0.35% | $38.43 | $56.90 | +48.1% | $8.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RACC RESEARCH ALLIANCE CORP CL A | 0.35% | $10.72 | $10.83 | +1.0% | $8.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMAN AMANAT ACQUISITION CORP CL A | 0.34% | $10.16 | $10.67 | +5.0% | $8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENTX ENTERA BIO LTD | 0.33% | $2.91 | $2.91 | 0.0% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVA INVENTIVA SA - ADR | 0.32% | $4.30 | $3.69 | -14.3% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JATT JATT II ACQUISITION CORP | 0.32% | $11.29 | $11.18 | -1.0% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.32% | $46.88 | $44.65 | -4.8% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNAQU RAINIER ACQUISITION CORP | 0.32% | $10.17 | $10.17 | 0.0% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCCC C4 THERAPEUTICS INC | 0.32% | $3.47 | $3.33 | -3.9% | $7.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MPLT MAPLIGHT THERAPEUTICS INC | 0.31% | $10.56 | $10.19 | -3.5% | $7.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SVRA SAVARA INC | 0.31% | $2.87 | $5.16 | +79.7% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CATX PERSPECTIVE THERAPEUTICS INC | 0.31% | $3.22 | $2.75 | -14.6% | $7.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.30% | — | — | — | $6.9M | |
SLN SILENCE THERAPEUTICS PLC-ADR | 0.29% | $9.87* | $10.93 | +10.8% | $6.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHVN BIOHAVEN LTD | 0.29% | $14.97 | $13.35 | -10.8% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASND ASCENDIS PHARMA A/S | 0.28% | $266.72 | $227.83 | -14.6% | $6.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DXYZ DESTINY TECH100 INC | 0.28% | $30.85 | $30.85 | 0.0% | $6.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
YARW YARROW BIOSCIENCE INC | 0.27% | $22.52 | $22.52 | 0.0% | $6.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TCGX TCGX ACQUISITION CORP-A | 0.27% | $12.51 | $12.51 | 0.0% | $6.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RACD RESEARCH ALLIANCE CORP IV-A | 0.26% | $11.84 | $11.84 | 0.0% | $6.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OKUR ONKURE THERAPEUTICS INC-A | 0.26% | $3.62 | $2.72 | -24.8% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.26% | $2.54 | $2.72 | +7.2% | $6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DMRA DAMORA THERAPEUTICS INC | 0.25% | $21.28 | $21.28 | 0.0% | $6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PLRX PLIANT THERAPEUTICS INC | 0.25% | $1.20 | $1.08 | -9.7% | $6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLYS MINERALYS THERAPEUTICS INC | 0.24% | $24.96 | $25.13 | +0.7% | $5.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OACCU OAKTREE ACQUISITION III LIFE | 0.24% | $10.14 | $10.89 | +7.4% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EQ EQUILLIUM INC | 0.24% | $1.45 | $1.62 | +12.4% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QURE UNIQURE NV | 0.24% | $45.45 | $24.16 | -46.8% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIIB BIOGEN INC | 0.23% | $191.41 | $225.88 | +18.0% | $5.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRYS KRYSTAL BIOTECH INC | 0.23% | $181.75 | $332.56 | +83.0% | $5.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IFRX INFLARX NV | 0.23% | $2.17 | $1.80 | -17.0% | $5.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRRO KORRO BIO INC | 0.23% | $11.32 | $9.91 | -12.5% | $5.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 0.23% | $6.52 | $3.38 | -48.1% | $5.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.22% | $11.91 | $13.42 | +12.7% | $5.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARDX ARDELYX INC | 0.22% | $3.44 | $3.42 | -0.6% | $5.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WHWK WHITEHAWK THERAPEUTICS INC | 0.21% | $4.41 | $3.76 | -14.8% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHAVU BHAV ACQUISITION CORP | 0.21% | $9.97 | $10.15 | +1.8% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JTTT JATT III ACQUISITION CORP | 0.21% | $11.02 | $11.02 | 0.0% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAPR CAPRICOR THERAPEUTICS INC | 0.21% | $8.18 | $9.47 | +15.7% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRME PRIME MEDICINE INC | 0.21% | $3.48 | $3.05 | -12.3% | $4.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSP INSPIRE MEDICAL SYSTEMS INC | 0.21% | $50.91 | $69.36 | +36.2% | $4.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARS TARSUS PHARMACEUTICALS INC | 0.20% | $76.25 | $76.25 | 0.0% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGNX MACROGENICS INC | 0.20% | $3.88 | $3.86 | -0.6% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BOLD BOUNDLESS BIO INC | 0.20% | $2.50 | $2.51 | +0.4% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABOS ACUMEN PHARMACEUTICALS INC | 0.20% | $1.89 | $2.22 | +17.7% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DHR DANAHER CORP | 0.20% | $222.14 | $221.55 | -0.3% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALEC ALECTOR INC | 0.20% | $1.85 | $1.85 | +0.2% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.20% | — | — | — | $4.6M | |
PFE PFIZER INC | 0.20% | $24.82* | $28.52 | +14.9% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARWR ARROWHEAD PHARMACEUTICALS IN | 0.19% | $29.34* | $65.45 | +123.1% | $4.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.19% | — | — | — | $4.5M | |
PMVP PMV PHARMACEUTICALS INC | 0.19% | $1.65 | $1.67 | +1.3% | $4.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RARE ULTRAGENYX PHARMACEUTICAL IN | 0.19% | $15.03 | $15.03 | 0.0% | $4.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.18% | $23.20 | $16.11 | -30.6% | $4.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ONC BEONE MEDICINES LTD-ADR | 0.18% | $296.97 | $365.94 | +23.2% | $4.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CGON CG ONCOLOGY INC | 0.18% | $29.67 | $70.89 | +138.9% | $4.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACHV ACHIEVE LIFE SCIENCES INC | 0.18% | $7.59 | $8.09 | +6.6% | $4.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 0.16% | $18.71 | $18.05 | -3.5% | $3.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ISRG INTUITIVE SURGICAL INC | 0.16% | $424.98 | $406.63 | -4.3% | $3.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GMED GLOBUS MEDICAL INC - A | 0.16% | $81.39 | $74.90 | -8.0% | $3.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 0.16% | $8.54 | $8.33 | -2.5% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NXTC NEXTCURE INC | 0.15% | $5.01 | $5.01 | 0.0% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNTX REIN THERAPEUTICS INC | 0.15% | $1.04 | $0.80 | -22.7% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DCTH DELCATH SYSTEMS INC | 0.15% | $6.94* | $15.97 | +130.1% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 0.15% | $1.80 | $2.42 | +34.7% | $3.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.14% | $14.37 | $14.59 | +1.5% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHVS PHARVARIS NV | 0.14% | $24.56 | $31.72 | +29.1% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZURA ZURA BIO LTD | 0.14% | $5.09 | $4.16 | -18.2% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGLT AGILITY ROBOTICS INC | 0.14% | $12.69 | $11.62 | -8.4% | $3.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.13% | — | — | — | $3.1M | |
BMRN BIOMARIN PHARMACEUTICAL INC | 0.13% | $58.90 | $60.00 | +1.9% | $3.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMS NEWAMSTERDAM PHARMA CO NV | 0.12% | $18.89 | $24.32 | +28.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LONA LEONABIO INC | 0.12% | $8.78 | $3.57 | -59.3% | $2.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KROS KEROS THERAPEUTICS INC | 0.12% | $10.96* | $11.40 | +4.0% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENGN ENGENE THERAPEUTICS INC | 0.11% | $1.73 | $2.00 | +15.6% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARA PROTARA THERAPEUTIC INC | 0.11% | $5.33 | $3.05 | -42.8% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRB SPRUCE BIOSCIENCES INC | 0.11% | $82.46 | $48.58 | -41.1% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRY ARS PHARMACEUTICALS INC | 0.10% | $8.94 | $4.31 | -51.8% | $2.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CHRS COHERUS ONCOLOGY INC | 0.10% | $1.21 | $1.21 | +0.2% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNA ATRIUM THERAPEUTICS INC | 0.09% | $9.38 | $8.28 | -11.7% | $2.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MSLE SATELLOS BIOSCIENCE INC | 0.09% | $6.01 | $8.50 | +41.4% | $2.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDT MEDTRONIC PLC | 0.09% | $86.29 | $86.29 | 0.0% | $2.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.09% | $2.28 | $1.35 | -40.8% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLMD RELMADA THERAPEUTICS INC | 0.09% | $6.26 | $3.77 | -39.8% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIOA BIOAGE LABS INC | 0.08% | $7.09 | $7.09 | 0.0% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 0.08% | $16.69 | $24.95 | +49.4% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HOWL WEREWOLF THERAPEUTICS INC | 0.08% | $0.92 | $0.92 | 0.0% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INO INOVIO PHARMACEUTICALS INC | 0.08% | $1.16 | $1.22 | +5.2% | $1.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELDN ELEDON PHARMACEUTICALS INC | 0.07% | $1.52 | $2.53 | +66.7% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.07% | $72.03 | $49.82 | -30.8% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSX BOSTON SCIENTIFIC CORP | 0.07% | $51.03 | $43.65 | -14.5% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCIIU COHEN CIRCLE ACQUISITION COR | 0.07% | $10.28 | $10.46 | +1.8% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WVE WAVE LIFE SCIENCES INC | 0.06% | $3.70 | $3.70 | 0.0% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.06% | $1.10 | $0.87 | -20.9% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXRX LEXICON PHARMACEUTICALS INC | 0.06% | $1.56 | $1.88 | +20.2% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRTC IRHYTHM HOLDINGS INC | 0.06% | $114.95 | $113.66 | -1.1% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRSA KORSANA BIOSCIENCES INC | 0.06% | $32.00 | $32.00 | 0.0% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LEGN LEGEND BIOTECH CORP-ADR | 0.06% | $19.89 | $19.89 | 0.0% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRBP CORBUS PHARMACEUTICALS HOLDI | 0.06% | $8.65 | $6.82 | -21.1% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.05% | $9.51 | $11.52 | +21.2% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NGNE NEUROGENE INC | 0.05% | $28.47 | $27.82 | -2.3% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
868459108 SUPERNUS PHARMACEUTICALS | 0.05% | $48.77 | $43.04 | -11.8% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AEXA AMERICAN EXCEPTIONALISM-CL A | 0.05% | $11.33 | $11.14 | -1.6% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RCKT ROCKET PHARMACEUTICALS INC | 0.05% | $6.76 | $2.63 | -61.1% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECX TECTONIC THERAPEUTIC INC | 0.05% | $21.98 | $23.29 | +5.9% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CUE CUE BIOPHARMA INC | 0.05% | $31.56 | $25.87 | -18.0% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STIP ISHARES 0-5 YEAR TIPS BOND E | 0.05% | $100.59 | $99.70 | -0.9% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NVO NOVO-NORDISK A/S-SPONS ADR | 0.05% | $36.79 | $37.91 | +3.0% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.04% | — | — | — | $1M | |
GRCE GRACE THERAPEUTICS INC | 0.04% | $2.15 | $2.15 | 0.0% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTX BIONTECH SE-ADR | 0.04% | $98.30 | $98.30 | 0.0% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KOD KODIAK SCIENCES INC | 0.04% | $94.80 | $94.80 | 0.0% | $995.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRAX FIRST TRACKS BIOTHERAPEUTICS | 0.04% | $20.12 | $35.44 | +76.1% | $988.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PMN PROMIS NEUROSCIENCES INC | 0.04% | $12.70 | $10.52 | -17.2% | $976.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SIBN SI-BONE INC | 0.04% | $15.64 | $18.80 | +20.2% | $940K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNYA TENAYA THERAPEUTICS INC | 0.04% | $0.71 | $0.60 | -15.3% | $938.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTRA NATERA INC | 0.04% | $229.09 | $413.31 | +80.4% | $887.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALXO ALX ONCOLOGY HOLDINGS INC | 0.04% | $1.97 | $1.39 | -29.4% | $869.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GPCR STRUCTURE THERAPEUTICS INC | 0.04% | $45.52 | $31.27 | -31.3% | $859.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERA VERA THERAPEUTICS INC | 0.04% | $43.88 | $32.29 | -26.4% | $849.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGOV ISHARES 0-3 MONTH TREASURY B | 0.03% | $100.68 | $100.68 | 0.0% | $805.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARE ALEXANDRIA REAL ESTATE EQUIT | 0.03% | $48.53 | $47.46 | -2.2% | $802.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EOLS EVOLUS INC | 0.03% | $6.27 | $8.00 | +27.6% | $800K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CORZ CORE SCIENTIFIC INC | 0.03% | $15.98 | $15.98 | 0.0% | $799K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LUNG PULMONX CORP | 0.03% | $2.28 | $1.91 | -16.1% | $772.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTB CONNECT BIOPHARMA HOLDINGS L | 0.03% | $2.62 | $1.10 | -58.0% | $770K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDYA IDEAYA BIOSCIENCES INC | 0.03% | $27.21 | $38.42 | +41.2% | $768.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECH BIO-TECHNE CORP | 0.03% | $72.47 | $72.47 | 0.0% | $760.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VCRE VICORE PHARMA HOLDING AB ADR | 0.03% | $9.51 | $9.51 | 0.0% | $759.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LRMR LARIMAR THERAPEUTICS INC | 0.03% | $3.02 | $3.19 | +5.8% | $759.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IOVAPut IOVANCE BIOTHERAPEUTICS INC | 0.03% | — | — | — | $741K |
ERAS ERASCA INC | 0.03% | $14.66 | $14.66 | 0.0% | $733K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RPRX ROYALTY PHARMA PLC- CL A | 0.03% | $52.83 | $58.36 | +10.5% | $729.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TXMD THERAPEUTICSMD INC | 0.03% | $2.23* | $2.03 | -9.1% | $695.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GILD GILEAD SCIENCES INC | 0.03% | $122.74 | $149.05 | +21.4% | $692.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KNSA KINIKSA PHARMACEUTICALS INTE | 0.03% | $28.05 | $74.61 | +166.0% | $690.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.03% | $17.12 | $8.26 | -51.8% | $680.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GERN GERON CORP | 0.03% | $2.04* | $1.23 | -39.7% | $622.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
23282WAE0 CYTOKINETICS INC PRN | 0.03% | — | — | — | $621.2K |
ARTV ARTIVA BIOTHERAPEUTICS INC | 0.03% | $9.70 | $7.12 | -26.6% | $618.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RZLT REZOLUTE INC | 0.03% | $4.05 | $4.14 | +2.1% | $615.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VSTM VERASTEM INC | 0.02% | $5.21 | $8.05 | +54.6% | $586K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRVI TREVI THERAPEUTICS INC | 0.02% | $14.32 | $14.32 | 0.0% | $584.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PYPD POLYPID LTD | 0.02% | $4.34 | $5.27 | +21.4% | $547.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNAC CARTESIAN THERAPEUTICS INC | 0.02% | $10.42 | $7.21 | -30.8% | $532.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GTERU GLOBA TERRA ACQUISITION CORP | 0.02% | $10.17 | $10.46 | +2.9% | $523K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPTX SEAPORT THERAPEUTICS INC | 0.02% | $21.72 | $20.17 | -7.1% | $504.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
USFR WISDOMTREE FLOATING RATE TRE | 0.02% | $50.24* | $50.39 | +0.3% | $503.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASMB ASSEMBLY BIOSCIENCES INC | 0.02% | $25.88 | $23.49 | -9.2% | $503.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNKD MANNKIND CORP | 0.02% | $3.90 | $3.90 | 0.0% | $461K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDGL MADRIGAL PHARMACEUTICALS INC | 0.02% | $431.22 | $503.96 | +16.9% | $451K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARVN ARVINAS INC | 0.02% | $7.02 | $7.74 | +10.2% | $445.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALMS ALUMIS INC | 0.02% | $7.39 | $7.39 | 0.0% | $443.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IBIO IBIO INC | 0.02% | $1.86 | $1.18 | -36.5% | $443.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KARD KARDIGAN INC | 0.02% | $14.75 | $14.75 | 0.0% | $442.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPRX KIORA PHARMACEUTICALS INC | 0.02% | $4.11 | $2.56 | -37.7% | $429.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KURA KURA ONCOLOGY INC | 0.02% | $7.31 | $10.71 | +46.6% | $428.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QTTB Q32 BIO INC | 0.02% | $8.27 | $8.27 | 0.0% | $413.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IHI ISHARES U.S. MEDICAL DEVICES | 0.02% | $50.04 | $51.15 | +2.2% | $393.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BABA ALIBABA GROUP HOLDING-SP ADR | 0.02% | $178.73 | $107.54 | -39.8% | $384.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IBRX IMMUNITYBIO INC | 0.02% | $9.44 | $9.44 | 0.0% | $377.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNSP CNS PHARMACEUTICALS INC | 0.02% | $4.78 | $5.30 | +10.9% | $371K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAUT NAUTILUS BIOTECHNOLOGY INC | 0.02% | $1.42 | $1.42 | 0.0% | $357.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMEA BIOMEA FUSION INC | 0.02% | $1.32 | $1.33 | +1.1% | $357K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRAW TRAWS PHARMA INC | 0.02% | $0.92 | $0.59 | -35.3% | $354.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SCYX SCYNEXIS INC | 0.01% | $4.32 | $4.94 | +14.3% | $342.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.01% | $92.38 | $85.48 | -7.5% | $333.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLTX MOONLAKE IMMUNOTHERAPEUTICS | 0.01% | $18.64 | $11.70 | -37.2% | $315.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHAT PHATHOM PHARMACEUTICALS INC | 0.01% | $8.62 | $7.30 | -15.3% | $313.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANTX AN2 THERAPEUTICS INC | 0.01% | $4.51 | $5.32 | +18.1% | $312.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WW WW INTERNATIONAL INC-NEW | 0.01% | $27.37 | $15.46 | -43.5% | $310.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.01% | — | — | — | $300.6K | |
ALT ALTIMMUNE INC | 0.01% | $3.04 | $2.86 | -5.9% | $294.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RXST RXSIGHT INC | 0.01% | $5.11 | $4.90 | -4.2% | $294K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCAPU PROCAP ACQUISITION CORP | 0.01% | $10.59 | $10.48 | -1.0% | $282.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DERM JOURNEY MEDICAL CORP | 0.01% | $7.08 | $6.84 | -3.4% | $270.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JD JD.COM INC-ADR | 0.01% | $34.98 | $26.60 | -24.0% | $266K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCAX BICARA THERAPEUTICS INC | 0.01% | $9.29 | $18.61 | +100.3% | $255.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STIM NEURONETICS INC | 0.01% | $1.45 | $2.34 | +61.4% | $234K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RXRX RECURSION PHARMACEUTICALS-A | 0.01% | $5.07 | $4.13 | -18.6% | $231.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTX CONTEXT THERAPEUTICS INC | 0.01% | $1.14 | $0.30 | -73.6% | $225.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COYA COYA THERAPEUTICS INC | 0.01% | $3.94 | $5.01 | +27.2% | $204.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CEPS CANTOR EQUITY PARTNERS VI -A | 0.01% | $10.10 | $10.20 | +1.0% | $204K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KLRS KALARIS THERAPEUTICS INC | 0.01% | $8.44 | $2.89 | -65.8% | $173.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NMRA NEUMORA THERAPEUTICS INC | 0.01% | $1.55 | $0.60 | -61.5% | $146.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OGN ORGANON & CO | 0.01% | $9.47 | $13.70 | +44.6% | $137K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMPX COMPASS THERAPEUTICS INC | 0.01% | $4.54 | $1.04 | -77.1% | $124.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRS ACLARIS THERAPEUTICS INC | 0.00% | $5.26 | $5.26 | 0.0% | $115.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NEUP NEUPHORIA THERAPEUTICS INC | 0.00% | $3.88 | $3.56 | -8.2% | $106.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAES CANTOR EQUITY PARTNERS VII-A | 0.00% | $10.09 | $10.10 | +0.1% | $101K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KYNB KYNTRA BIO INC | 0.00% | $6.65 | $6.65 | 0.0% | $95.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VYGR VOYAGER THERAPEUTICS INC | 0.00% | $5.94* | $2.68 | -54.9% | $93.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERU VERU INC | 0.00% | $2.14 | $2.66 | +24.3% | $93.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LABD DIRE DLY SP BT BE 3X ETF-USD | 0.00% | $7.03 | $7.03 | 0.0% | $92.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LITS LITE STRATEGY INC | 0.00% | $2.42 | $1.32 | -45.5% | $88.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIST MILESTONE PHARMACEUTICALS IN | 0.00% | $2.02 | $0.87 | -57.1% | $86.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CABA CABALETTA BIO INC | 0.00% | $3.11 | $1.92 | -38.3% | $76.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.00% | $4.10 | $4.10 | 0.0% | $70.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLNN CLENE INC | 0.00% | $6.16 | $4.08 | -33.7% | $61.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABUS ARBUTUS BIOPHARMA CORP | 0.00% | $3.83* | $4.78 | +24.9% | $50.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LGVN LONGEVERON INC-A | 0.00% | $2.69 | $2.69 | 0.0% | $29.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASPCR A SPAC III ACQUISITION CORP | 0.00% | $0.14 | $0.10 | -28.4% | $21.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRQR PROQR THERAPEUTICS NV | 0.00% | $5.30 | $1.66 | -68.7% | $16.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSAAR BEST SPAC I ACQUISITION - RT | 0.00% | $0.17 | $0.07 | -56.2% | $7.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DGAC.U DISCIPLINED GROWTH ACQUISITI | 0.00% | — | — | — | $0 |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Dec 31, 2023, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Jun 30, 2026, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Jun 30, 2026 and not reported for Q3 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| CRNX CRINETICS PHARMACEUTICALS IN | 2.09% | 1,222,080 | $45.7M | EXIT |
| IWMPut ISHARES RUSSELL 2000 ETF | 0.86% | 62,500 | $18.8M | EXIT |
| SPYPut SS SPDR S&P 500 ETF TRUST-US | 0.85% | 25,000 | $18.7M | EXIT |
| XBIPut SS SPDR S&P BIOTECH ETF | 0.49% | 67,400 | $10.7M | EXIT |
| 881624209 TEVA PHARMACEUTICAL INDS LTD | 0.43% | 277,848 | $9.4M | EXIT |
| FTH FAETH THERAPEUTICS INC | 0.41% | 361,010 | $9M | EXIT |
| FRNM FREENOME INC | 0.34% | 674,695 | $7.3M | EXIT |
| 36322Q206 DAMORA THERAPEUTICS INC | 0.33% | 280,000 | $7.3M | EXIT |
| BHF BRIGHTHOUSE FINANCIAL INC | 0.28% | 95,523 | $6M | EXIT |
| ATAI ATAIBECKLEY INC | 0.22% | 913,242 | $4.8M | EXIT |
| PRLD PRELUDE THERAPEUTICS INC | 0.22% | 900,900 | $4.8M | EXIT |
| APGE APOGEE THERAPEUTICS INC | 0.19% | 31,000 | $4.1M | EXIT |
| SGMT SAGIMET BIOSCIENCES INC-A | 0.15% | 437,500 | $3.4M | EXIT |
| OABI OMNIAB INC | 0.11% | 947,412 | $2.3M | EXIT |
| ORKA ORUKA THERAPEUTICS INC | 0.09% | 20,840 | $2M | EXIT |
| 92941V308 VYNE THERAPEUTICS INC | 0.09% | 2,950,000 | $1.9M | EXIT |
| MCK MCKESSON CORP | 0.09% | 2,500 | $1.9M | EXIT |
| AVTR AVANTOR INC | 0.06% | 130,000 | $1.3M | EXIT |
| 457637700 INMED PHARMACEUTICALS INC | 0.06% | 800,000 | $1.2M | EXIT |
| 23255M204 CYCLERION THERAPEUTICS INC | 0.05% | 298,757 | $1M | EXIT |
| EA ELECTRONIC ARTS INC | 0.05% | 4,936 | $1M | EXIT |
| 89422GAB3 TRAVERE THERAPEUTICS INC | 0.05% | 10,000 | $1M | EXIT |
| ACAD ACADIA PHARMACEUTICALS INC | 0.05% | 38,955 | $985.6K | EXIT |
| DYN DYNE THERAPEUTICS INC | 0.04% | 42,821 | $951.1K | EXIT |
| KVACFCall KEEN VISION ACQUISITION CORP | 0.04% | 75,000 | $930K | EXIT |
| Y95308105 WAVE LIFE SCIENCES LTD | 0.04% | 160,000 | $929.6K | EXIT |
| NUVL NUVALENT INC-A | 0.04% | 6,942 | $857.3K | EXIT |
| ADGM ADAGIO MEDICAL HOLDINGS INC | 0.04% | 1,205,447 | $785.5K | EXIT |
| AMLXPut AMYLYX PHARMACEUTICALS INC | 0.03% | 40,100 | $720.2K | EXIT |
| FWRD FORWARD AIR CORP | 0.03% | 48,241 | $651.7K | EXIT |
| SYK STRYKER CORP | 0.03% | 2,000 | $629.7K | EXIT |
| NVOCall NOVO-NORDISK A/S-SPONS ADR | 0.03% | 13,000 | $623.2K | EXIT |
| IOVA IOVANCE BIOTHERAPEUTICS INC | 0.03% | 146,090 | $607.7K | EXIT |
| CRBPCall CORBUS PHARMACEUTICALS HOLDI | 0.03% | 60,000 | $562.8K | EXIT |
| 23256X407 CYBIN INC | 0.02% | 81,278 | $537.2K | EXIT |
| BNTC BENITEC BIOPHARMA INC | 0.02% | 40,000 | $535.2K | EXIT |
| KIDS ORTHOPEDIATRICS CORP | 0.02% | 25,000 | $478.3K | EXIT |
| MRK MERCK & CO. INC. | 0.02% | 3,140 | $403.5K | EXIT |
| ANAB ANAPTYSBIO INC | 0.01% | 3,698 | $249.6K | EXIT |
| BCYC BICYCLE THERAPEUTICS PLC-ADR | 0.01% | 50,638 | $214.7K | EXIT |
| PSNL PERSONALIS INC | 0.01% | 15,000 | $201K | EXIT |
| QCLS Q/C TECHNOLOGIES INC | 0.01% | 50,000 | $195K | EXIT |
| CMMB CHEMOMAB THERAPEUTICS LTD | 0.01% | 80,000 | $129.6K | EXIT |
| STICall SOLIDION TECHNOLOGY INC | 0.01% | 13,500 | $125.4K | EXIT |
| TRDA ENTRADA THERAPEUTICS INC | 0.01% | 15,500 | $114.1K | EXIT |
| VTGN VISTAGEN THERAPEUTICS INC | 0.00% | 351,141 | $79.4K | EXIT |
| 54303L203 LONGEVERON INC | 0.00% | 108,406 | $76.2K | EXIT |
| 471871202 JASPER THERAPEUTICS INC | 0.00% | 140,000 | $58.9K | EXIT |
| 38341P102 GOSSAMER BIO INC | 0.00% | 212,531 | $35K | EXIT |
| 002120202 ATYR PHARMA INC | 0.00% | 50,685 | $30.2K | EXIT |
SEC filings for Q3 2026
- 13F-HR 0001940272-26-000033 · accepted Nov 16, 2026, 14:59 UTC
- 13F-HR/A 0001940272-26-000034 · accepted Nov 16, 2026, 21:29 UTC · NEW HOLDINGS